地诺单抗上市了吗？价格多少钱？

Is (Denosumab) on the market? How much does it cost? Denosumab (denosumab) is the first approved monoclonal antibody that specifically targets RANK ligand. RANK ligand is a transmembrane or soluble protein that is necessary for osteoclasts to maintain their structure, function, and survival. Denosumab (Denosumab) has a high affinity with RANKL, preventing RANK ligands from activating RANK on the surface of osteoclasts, inhibiting osteoclast activation and development, reducing bone resorption, increasing bone density and bone strength of both cortical bone and trabecular bone, promoting bone reconstruction, and reducing the incidence of vertebral, non-vertebral and hip fractures in postmenopausal osteoporotic women.

On May 27, 2019, Amgen China announced today that denosumab has been approved by the National Medical Products Administration for the treatment of giant cell tumors of bone that are unresectable or whose surgical resection may cause severe functional disability, including adults and adolescent patients with skeletal maturity (defined as at least 1 mature long bone and a body weight ≥45 kg). In 2018, denosumab was included in the list of overseas new drugs in urgent clinical need (first batch) and entered the rapid review channel of the National Medical Products Administration. This approval makes denosumab the first and currently the only drug for the treatment of giant cell tumor of bone, bringing patients an innovative treatment option to control disease progression and improve quality of life.

Although the country conditionally approved denosumab for marketing in May 2019, due to the conditional approval and the fact that it was only on the market for five months, the domestic selling price of this drug cannot be collected. What is certain is that as an imported original drug, new drug, and special effect drug, the domestic price of denosumab (Denosumab) must be very high. According to the editor of Medical Companion Travel, denosumab (Denosumab) currently on the market in the United States is 60mg/1ml tube/box, priced at US$1,169.98. The price is relatively expensive, and most families of patients with average economic levels cannot afford the high medical expenses. Fortunately, denosumab (Denosumab) produced by the American company Amgen has been launched in Turkey. The specification is 125mg/1ml tube/box, and the price is equivalent to RMB 3,000, which can be said to be high quality and low price. Therefore, more and more patients choose the drug (Denosumab) marketed in Türkiye by Amgen of the United States. If there is a need for patients, please consult the medical companion travel service.

Recommended related hot articles: /newsDetail/74111.html